Commentary: Next-Generation Drug-Coated Balloons: A New Era for Endovascular Therapy of the Femoropopliteal Arteries?

Abstract

Keywords

drug-coated balloon drug-eluting balloon femoropopliteal segment late lumen loss peripheral artery disease paclitaxel popliteal artery restenosis stenosis superficial femoral artery

Get full access to this article

View all access options for this article.

References

Tepe

Zeller

Albrecht

. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358:689–699.

Werk

Langner

Reinkensmeier

. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation. 2008;118:1358–1365.

Werk

Albrecht

Meyer

. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv. 2012;5:831–840.

Micari

Cioppa

Vadala

. 2-year results of paclitaxel-eluting balloons for femoropopliteal artery disease: evidence from a multicenter registry. J Am Coll Cardiol Interv. 2013;6:282–289.

Scheinert

Duda

Zeller

. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv. 2014;7:10–19.

Rosenfield

Jaff

White

. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.

Laird

Schneider

Tepe

. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.

Tepe

Laird

Schneider

. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.

Scheinert

Schmidt

Zeller

. German center subanalysis of the LEVANT 2 global randomized study of the Lutonix drug-coated balloon in the treatment of femoropopliteal occlusive disease. J Endovasc Ther. 2016;23:409–416.

10.

Schroeder

Meyer

Lux

. Two-year results of a low-dose drug-coated balloon for revascularization of the femoropopliteal artery: outcomes from the ILLUMENATE first-in-human study. Catheter Cardiovasc Interv. 2015;86:278–286.

11.

Scheinert

Schulte

Zeller

. Paclitaxel-releasing balloon in femoropopliteal lesions using a BTHC excipient: twelve-month results from the BIOLUX P-I randomized trial. J Endovasc Ther. 2015;22:14–21.

12.

Salisbury

Vilain

. Cost-effectiveness of endovascular femoropopliteal intervention using drug-coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II trial. JACC Cardiovasc Interv. 2016;9:2343–2352.

13.

Bausback

Willfort-Ehringer

Sievert

. Six-month results from the initial randomized study of the Ranger paclitaxel-coated balloon in the femoropopliteal segment. J Endovasc Ther. 2017;24:459–467.

14.

Diamantopoulos

Gupta

Zayed

. Paclitaxel-coated balloons and aneurysm formation in peripheral vessels. J Vasc Surg. 2015;62:1320–1322.

15.

Granada

Stenoien

Buszman

. Mechanisms of tissue uptake and retention of paclitaxel-coated balloons: impact on neointimal proliferation and healing. Open Heart. 2014;1:e000117.

16.

Gongora

Shibuya

Wessler

. Impact of paclitaxel dose on tissue pharmacokinetics and vascular healing: a comparative drug-coated balloon study in the familial hypercholesterolemic swine model of superficial femoral in-stent restenosis. JACC Cardiovasc Interv. 2015;8:1115–1123.

17.

Schmidt

Piorkowski

Gorner

. Drug-coated balloons for complex femoropopliteal lesions: two year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.

18.

Steiner

Schmidt

Bausback

. Midterm patency after femoropopliteal interventions: a comparison of standard and interwoven nitinol stents and drug-coated balloons in a single-center, propensity score-matched analysis. J Endovasc Ther. 2016;23:347–355.

19.

Fanelli

Cannavale

Gazzetti

. Calcium burden assessment and impact on drug-eluting balloons in peripheral arterial disease. Cardiovasc Intervent Radiol. 2014;37:898–907.

20.

Foley

Cotter

Kokkinidis

. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease [published online March 15, 2017]. Catheter Cardiovasc Interv. doi:10.1002/ccd.26984.

21.

Micari

Vadala

Castriota

. 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long study. JACC Cardiovasc Interv. 2016;9:950–956.